Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05945121 · ClinicalTrials.gov registry record · NA

Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

A NA study of Hematopoietic Stem Cell Transplant, sponsored by University of Michigan Rogel Cancer Center.

Recruiting
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT05945121 is a NA study of Hematopoietic Stem Cell Transplant that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 10 participants, below the 103-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05945121, a NA study of Hematopoietic Stem Cell Transplant, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.

RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipients.

Interventions

  • OTHER Cardio-oncology program

Study Locations (1)

Michigan

  • University of Michigan Rogel Cancer Center - Ann Arbor

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2023-08-25
Est. Completion 2027-08
Phase NA

What the Registry Record Tells You About NCT05945121

The ClinicalTrials.gov registry entry for NCT05945121 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 8 other Hematopoietic Stem Cell Transplant trials with a reported enrollment target (90% lower). The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematopoietic Stem Cell Transplant appearing as the primary indexed condition, and to 1 intervention - of which Cardio-oncology program is the first listed.

NCT05945121 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.

Frequently Asked Questions

What is clinical trial NCT05945121 about?

NCT05945121 is a clinical study titled "Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation". To assess the feasibility and preliminary effectiveness of a Cardio-Oncology Prehabilitation program in patients at high-risk of developing Cardiovascular (CV) events in improving Cardiorespiratory fitness (CRF) and reducing acute CV complications in Hematopoietic stem cell transplant (HSCT) recipie...

What is the current status of trial NCT05945121?

This trial is currently recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2023-08-25. Estimated completion is 2027-08.

What conditions does trial NCT05945121 study?

This clinical trial studies the following conditions: Hematopoietic Stem Cell Transplant.

What interventions are being tested in trial NCT05945121?

The interventions under investigation include: Cardio-oncology program (OTHER).

Who is sponsoring clinical trial NCT05945121?

This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05945121 being conducted?

This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic Stem Cell Transplant

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.